The approach could enable 30-minute testing for a heart condition that is newly treatable following recent drug approvals.

Owner Zishan Alvi submitted claims for COVID-19 tests that were either never performed or were performed incorrectly, releasing potentially false negative test results to patients.

NEW YORK – Qiagen announced on Wednesday that it has launched a third-party partnering program for its clinical digital PCR platform and signed an agreement with the program's inaugural partner, South ...

Caris plans to use the proceeds from its IPO to pay off about $400 million worth of debt, he noted, and it also intends to use the funds to drive toward profitability next year and continue expanding ...

The firm said in May it was considering the surcharge following disclosure of a $40 million tariff-related headwind for 2025.

Adding the firm's multi-cancer early detection test to standard-of-care screening demonstrated substantially greater additional cancer detection than in Pathfinder.

The shares are expected to begin trading on June 18 under the ticker symbol CAI, and the offering is expected to close on June 20.

NEW YORK – With new data and plans for additional clinical validation in the works, liquid biopsy firm PanGia Biotech is making strides toward commercialization of its urine-based prostate cancer ...

Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

NEW YORK – Linear Diagnostics is hoping to build a broader test menu for its rapid molecular testing platform to complement its first test for sexually transmitted infections, the development of which ...

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.